Title |
A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
|
---|---|
Published in |
Journal of Cancer, August 2015
|
DOI | 10.7150/jca.12819 |
Pubmed ID | |
Authors |
Jung Han Kim, Dae Young Zang, Ik-Joo Chung, Sang-Hee Cho, Keon Uk Park, Ho-Suck Oh, Kyung Hee Lee, Bong Hwa Lee, Min-Jeong Kim, Choong Kee Park, Boram Han, Hyeong Su Kim, Dae Ro Choi, Hun Ho Song, Joo Young Jung |
Abstract |
Capecitabine plus oxaliplatin (XELOX) is considered one of the primary chemotherapy regimens for patients with metastatic colorectal cancer (CRC). Oxaliplatin plus S-1 (OS) has also demonstrated significant efficacy in CRC. We performed this randomized phase II study to evaluate the efficacy and toxicity of XELOX versus OS as first-line chemotherapy in patients with metastatic CRC. Patients were assigned randomly to receive either OS or XELOX chemotherapy. Oxaliplatin was administered intravenously to all patients at a dose of 130 mg/m(2) on day 1. Patients received either S-1 (40 mg/m(2)) or capecitabine (1,000 mg/m(2)), twice a day for 2 weeks, followed by a 1-week rest. Forty-two patients were assigned to the OS arm and 44 to the XELOX arm. The overall response rate was 33.3% (95% CI, 18.8-47.2) in the OS arm and 40.9% (95% CI, 25.5-54.4) in the XELOX arm (P = 0.230). The disease control rate was significantly higher in the OS arm than the XELOX arm [92.9% (95% CI, 83.7-100) versus 77.3% (95% CI, 64.5-89.4), P = 0.044]. With a median follow up of 17.9 months, the median progression-free survival was 6.1 months in the OS arm and 7.4 months in the XELOX arm, respectively (P = 0. 599). The median survival time was 18.7 months in the OS arm and 20.1 months in the XELOX arm (P = 0.340). The most common grade 3/4 hematologic toxicity was thrombocytopenia in both arms (19.0% for OS and 28.6% for XELOX). Grade 3/4 neutropenia was observed more frequently in the XELOX arm than the OS arm (16.7% vs. 2.4%, P = 0.026). Both OS and XELOX were effective and well tolerated in patients with metastatic CRC. Our results indicate that the combination of oxaliplatin and S-1 is a possible additional therapeutic strategy for such patients. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 27% |
Student > Doctoral Student | 2 | 18% |
Lecturer | 1 | 9% |
Student > Bachelor | 1 | 9% |
Student > Ph. D. Student | 1 | 9% |
Other | 2 | 18% |
Unknown | 1 | 9% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 36% |
Psychology | 3 | 27% |
Nursing and Health Professions | 3 | 27% |
Unknown | 1 | 9% |